We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+7.14%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$814M
(+22%)
Cap. Flow
+$233M
Cap. Flow
% of AUM
5.17%
Top 10 Holdings %
Top 10 Hldgs %
40.45%
Holding
134
New
22
Increased
42
Reduced
20
Closed
29
Avg Time Held Equity + Options
0.5
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$94.6M |
| 2 |
AstraZeneca
AZN
|
+$82.2M |
| 3 |
Baxter International
BAX
|
+$68.1M |
| 4 |
Caribou Biosciences
CRBU
|
+$60.5M |
| 5 |
Stevanato
STVN
|
+$59.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maravai LifeSciences
MRVI
|
+$124M |
| 2 |
Medtronic
MDT
|
+$66.4M |
| 3 |
Biogen
BIIB
|
+$63.7M |
| 4 |
NeoGenomics
NEO
|
+$61.7M |
| 5 |
Eli Lilly
LLY
|
+$58.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.27% |
| 2 | Miscellaneous | 13.11% |
| 3 | Technology | 0.99% |
| 4 | Financials | 0.64% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Stevanato
STVN
$5.16B
| $64.3M | 1.43% |
+2,541,893
| New | +$59.9M |
2021 Q3
0 quarters
|
|
27
Sotera Health
SHC
$5.11B
| $62.2M | 1.38% |
2,378,000
+468,000
| +25% | +$11.3M |
2020 Q4
3 quarters
|
|
28
IDEAYA Biosciences
IDYA
$3.17B
| $62.1M | 1.38% |
2,437,000
+367,000
| +18% | +$8.57M |
2021 Q1
2 quarters
|
|
|
29
Caribou Biosciences
CRBU
$50.4M
| $59.1M | 1.31% |
+2,474,067
| New | +$60.5M |
2021 Q3
0 quarters
|
|
30
DELISTED
CATALENT, INC.
CTLT
| $53M | 1.17% |
398,000
-142,000
| -26% | -$17.7M |
2020 Q3
4 quarters
|
|
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $48.1M | 1.07% |
4,457,831
+2,335,767
| +110% | +$21.3M |
2020 Q4
3 quarters
|
|
32
Legend Biotech
LEGN
$3.59B
| $45.2M | 1% |
894,000
+269,000
| +43% | +$11.2M |
2021 Q2
1 quarter
|
|
|
OCDX
33
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $44.3M | 0.98% |
+2,398,000
| New | +$48.3M |
2021 Q3
0 quarters
|
|
34
Pfizer
PFE
$169B
| $44.2M | 0.98% |
+1,026,800
| New | +$45.5M |
2021 Q3
0 quarters
|
|
35
Arrowhead Research
ARWR
$7.9B
| $42.1M | 0.93% |
673,700
+569,700
| +548% | +$36.9M |
2021 Q2
1 quarter
|
|
36
Shattuck Labs
STTK
$544M
| $41.3M | 0.91% |
2,025,000
+84,800
| +4% | +$1.81M |
2020 Q4
3 quarters
|
|
37
Ultragenyx Pharmaceutical
RARE
$1.43B
| $41M | 0.91% |
+455,000
| New | +$41.1M |
2021 Q3
0 quarters
|
|
38
Immunocore
IMCR
$1.51B
| $40.6M | 0.9% |
1,095,600
+494,600
| +82% | +$16.7M |
2021 Q1
2 quarters
|
|
|
RNAM
39
DELISTED
Avidity Biosciences
RNAM
| $40.5M | 0.9% |
+1,645,000
| New | +$35.8M |
2021 Q3
0 quarters
|
|
40
Iovance Biotherapeutics
IOVA
$6.17B
| $36.1M | 0.8% |
+1,462,200
| New | +$34.5M |
2021 Q3
0 quarters
|
|
41
Insmed
INSM
$21B
| $35.6M | 0.79% |
1,292,000
+141,950
| +12% | +$3.72M |
2021 Q2
1 quarter
|
|
42
DELISTED
Exact Sciences
EXAS
| $35.2M | 0.78% |
369,000
-221,000
| -37% | -$23.3M |
2020 Q4
3 quarters
|
|
43
Compass Pathways
CMPS
$1.49B
| $34.7M | 0.77% |
1,162,000
+162,000
| +16% | +$5.44M |
2021 Q2
1 quarter
|
|
44
Alphatec Holdings
ATEC
$1.62B
| $34M | 0.75% |
2,786,000
+165,000
| +6% | +$2.3M |
2020 Q4
3 quarters
|
|
45
Intellia Therapeutics
NTLA
$1.6B
| $33.7M | 0.75% |
251,000
-129,000
| -34% | -$19.5M |
2021 Q2
1 quarter
|
|
46
NovaBridge Biosciences American Depositary Shares
NBP
$146M
| $32.9M | 0.73% |
454,000
-275,000
| -38% | -$19.9M |
2020 Q3
4 quarters
|
|
|
SPNE
47
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $30.6M | 0.68% |
1,943,000
+418,002
| +27% | +$7.15M |
2021 Q2
1 quarter
|
|
|
BLU
48
DELISTED
BELLUS Health Inc.
BLU
| $30.3M | 0.67% |
4,942,000
+692,000
| +16% | +$2.62M |
2020 Q4
3 quarters
|
|
49
Kymera Therapeutics
KYMR
$8.71B
| $30.2M | 0.67% |
+514,500
| New | +$29.8M |
2021 Q3
0 quarters
|
|
|
CYT
50
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $29.5M | 0.65% |
1,683,441
-124,953
| -7% | -$2.34M |
2021 Q2
1 quarter
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q3 2021 Portfolio in Review
As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Avidity Partners Management deployed $233M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.
- Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
- Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
- Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
- Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
- Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
- Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
- Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.
Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.